Finally, we performed Kaplan-Meier survival analysis using The Cancer Genome Atlas (TCGA) datasets for HCC,30 which validated our in vitro findings and revealed a clinical correlation: elevated GPD1L and GPD2 expression in sorafenib-treated patients was associated with reduced overall survival (Fig. 5h). Here, GPD2 is linked to hepatocellular carcinoma.